Conjugate Vaccines

Conjugate Vaccines target several leading causes of vaccine-preventable deaths. Conjugate vaccines also have antigens or toxoids, often from the same bacteria, linked to the sugar molecules. Conjugate vaccines only use a small part of a bacterium linked to carrier protein. Conjugate vaccines are primarily used for the prevention of bacterial infections. Polysaccharide protein conjugate vaccines comprise of polysaccharides, generally from the surface coat of bacteria, linked to protein carriers. The advantages of the conjugate vaccines are their capacity to create immunological memory and to decrease asymptomatic carriage of the microbes, resulting in marked herd immunity. Conjugate vaccines can reduce complexity and increase coverage

  • Track 1-1 Epidemiology and Methodology├é┬á
  • Track 2-2 Glycoconjugate Vaccines
  • Track 3-3 Hib Vaccines
  • Track 4-4 Vaccines Formulation and Technologies used in Conjugated Vaccines
  • Track 5-5 N. meningitidis Vaccines
  • Track 6-6 S. pneumoniae Vaccines

Related Conference of Vaccines